Valuation: China Isotope & Radiation Corporation

Market Cap 3.69B 4.32B 550M 477M 450M 408M 766M 52.73B 771M 5.37B 2.07B 26.75B 2.07B 2.02B 85.04B P/E 2024
8.03x
P/E 2025 17.7x
Enterprise Value 3.81B 4.45B 568M 492M 464M 421M 790M 54.43B 796M 5.55B 2.14B 27.61B 2.13B 2.09B 87.78B EV / Sales 2024
0.42x
EV / Sales 2025 0.82x
Free-Float
91.21%
Yield 2024
3.74%
Yield 2025 1.69%
08-28 China Isotope & Radiation Corporation Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-28 China Isotope & Radiation Corporation Proposes Interim Dividend for the Six Months Ended 30 June 2026, Payable on 27 November 2026 CI
08-28 China Isotope & Radiation Corporation Announces Resignation of Zhang Junqi as an Executive Director, A Member of the Strategy Committee of the Board and A Member of the Science and Technology Innovation Committee of the Board, Effective August 28, 2026 CI
08-28 China Isotope & Radiation Corporation Announces CEO Changes, Effective August 28, 2026 CI
07-06 China Isotope to Form JV With Associate MT
07-03 China Isotope & Radiation Corporation and CNNC Yuanke Enter into Shareholders? Agreement to Establish Joint Venture Company CNNC Fuyuan CI
06-18 China Isotope & Radiation Corporation Approves Final Dividend for the Year Ended 31 December 2025, Payable on Before 17 August 2026 CI
06-18 China Isotope & Radiation Corporation Appoints Zhang Guoliang as A Member of Legal Affairs Committee of the Board and A Member of Science and Technology Innovation Committee of the Board CI
05-27 China Isotope Proposes Auditor Change MT
05-26 China Isotope & Radiation Corporation Announces Ma Xiaoyu Resignation of Ma Xiaoyu as an Executive Director Member of the Legal Affairs Committee Science and Technology Innovation Committee, Effective May 26, 2026 CI
03-28 China Isotope & Radiation final cash dividend of RMB0.2264 per share RE
03-27 China Isotope & Radiation Corporation Proposes Final Dividend for the Year Ended December 31, 2025, Payable Before 17 August 2026 CI
03-27 China Isotope & Radiation Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
1 day+0.07%
1 week-7.41%
Current month-18.82%
1 month-21.10%
3 months-26.39%
6 months-35.22%
Current year-33.17%
1 week 13.06
Extreme 13.06
14.3
1 month 13.06
Extreme 13.06
17.49
Current year 13.06
Extreme 13.06
24.28
1 year 13.06
Extreme 13.06
25
3 years 9.03
Extreme 9.03
25
5 years 9.03
Extreme 9.03
26.5
10 years 9.03
Extreme 9.03
35.4
Manager TitleAgeSince
Corporate Secretary - 30/08/2024
Corporate Secretary - 30/08/2024
Comptroller/Controller/Auditor 52 18/12/2015
Director TitleAgeSince
Director/Board Member 57 22/02/2017
Director/Board Member 54 28/06/2019
Director/Board Member 54 30/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-7.41%-19.50%+8.17% 550M
+2.15%+5.31%+209.42%+474.09% 22.52B
+1.05%+0.35%-36.86%-21.33% 9.72B
+4.34%+11.07%+445.77%+46.51% 9.13B
+4.64%+9.47%-17.96% - 7.36B
+0.11%-0.01%+94.10%+54.95% 6.55B
+0.84%-3.89%-28.39%-21.92% 5.68B
+0.03%+0.41%-5.59%-19.76% 4.22B
+0.27%-14.71%+51.31%+61.83% 3.7B
+1.89%-2.40%-22.85%-30.45% 2.7B
Average +1.58%-0.09%+66.94%+61.35% 7.21B
Weighted average by Cap. +2.07%+2.28%+122.64%+172.88%

Financials

2024 2025
Net sales 7.57B 8.85B 1.13B 978M 923M 837M 1.57B 108B 1.58B 11.02B 4.25B 54.86B 4.24B 4.14B 174B 7.19B 8.4B 1.07B 928M 875M 794M 1.49B 103B 1.5B 10.46B 4.03B 52.06B 4.02B 3.93B 165B
Net income 407M 475M 60.57M 52.48M 49.53M 44.93M 84.29M 5.81B 84.9M 592M 228M 2.95B 227M 222M 9.36B 327M 383M 48.77M 42.26M 39.88M 36.18M 67.87M 4.67B 68.36M 476M 184M 2.37B 183M 179M 7.54B
Net Debt -109M -127M -16.23M -14.06M -13.27M -12.04M -22.58M -1.56B -22.74M -158M -61.06M -789M -60.94M -59.6M -2.51B 119M 139M 17.7M 15.34M 14.47M 13.13M 24.63M 1.7B 24.81M 173M 66.61M 861M 66.49M 65.02M 2.74B
Logo China Isotope & Radiation Corporation
China Isotope & Radiation Corp is a China-based company mainly engaged in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products. The Company operates five business segments. Pharmaceuticals segment is engaged in providing imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test (UBT) kits and analyzers and in vitro diagnostic reagents and kits. Radioactive Source Products segment is engaged in providing various medical and industrial radioactive sources products as well as provision of related technical services. Irradiation segment is engaged in providing sterilization services. Radiation Therapy Equipment and Related Services segment is engaged in manufacturing Radiation therapy equipment. Other Businesses segment is engaged in providing trade services in relation to imported radioactive source, medical nuclides, imported radiopharmaceuticals, and other products.
Employees
3,655
Date Price Change Volume
15/09/26 HK$13.50 +0.07% 62,800
14/09/26 HK$13.49 +0.97% 217,400
11/09/26 HK$13.36 -0.96% 92,000
10/09/26 HK$13.49 -3.37% 433,200
09/09/26 HK$13.96 -2.51% 275,000

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1763 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!